Intravenous Anticoagulants Market Size, Share, Analysis 2031
Intravenous Anticoagulants Market Size, Share, Analysis 2031
Segments - Intravenous Anticoagulants Market By Type (Heparin, Fondaparinux, Direct Thrombin Inhibitors), Application (Unfractionated Heparin (UFH), Low Molecular Weight Heparin (LMWH), Fondaparinux, and Direct Thrombin Inhibitors), End use (Hospital, Clinics, and Ambulatory Centers), and Regions (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
Upcoming
| Report ID :HC-6105
| 4.8 Rating
| 68 Reviews
| 353 Pages
| Format :
Report Description
Intravenous Anticoagulants Market Outlook 2031:
The Global Intravenous Anticoagulants Market was estimated at USD 13,479.9 Million in 2022 and is anticipated to reach USD 22,682.0 Million by 2031, expanding at a CAGR of 5.96% during the forecast period.
Intravenous anticoagulants are medications that are administered intravenously to prevent blood clots. It is given to patients who are at high risk of developing clots, to decrease the chances of the appearance of serious conditions, including strokes and heart attacks.
A blood clot is a barrier produced by the blood itself to stop bleeding from the site of an injury. However, if the blood clots do not stick to the site of an injury or form in the bloodstream, it proves to be extremely dangerous.
These get stuck in a small blood vessel if clots are large. When that small vessel is in a critical part of the body such as the heart, brain, or lungs, these clots obstruct the blood flow of these organs, which are necessary to survive.
Macro-economic Factors
Population Demographics
The demographic profile of a population, particularly the geriatric population, is one of the important factors influencing the intravenous anticoagulants market. The high chance or incidence of blood clots in elder people influences the demand for intravenous anticoagulants.
The rapid surge in the number of coronary artery bypass surgeries and related conditions among the aging population significantly influences the demand for intravenous anticoagulants.
For instance, according to the American Health Association, around 89.4% of males and 90.8% of females aged 80 and above had cardiovascular diseases (CVD) in 2021. Additionally, the National Library of Medicine (NLM) stated that many older patients are frequently undergoing adult cardiac surgery.
Intravenous Anticoagulants Market Dynamics
Market Driver- Increasing Incidence Of Cardiovascular Diseases
Rising incidence of cardiovascular diseases across the globe is expected to drive the intravenous anticoagulants market during the forecast period.
For instance, according to a finding from the World Heart Federation, the number of CVD deaths is anticipated to increase from an estimated 18.9 million in 2020 to more than 22.2 million in 2030 and 32.3 million in 2050.
Anticoagulants are important in cardiovascular therapy and parenteral anticoagulants are widely used in cardiology, mostly in acute situations. Unfractionated heparin (UFH) is used in open heart CABG, open heart valve replacement/repair, transcatheter valve replacement, carotid artery, transmyocardial revascularization, aneurysm surgery, left atrial appendage, atrial fibrillation ablation, and percutaneous coronary intervention (PCI). Thus, the rising CVD diseases are anticipated to boost the demand for intravenous anticoagulants.
Market Driver- Rising Use of Anticoagulants in Cancer-associated Thrombosis (CAT)
Incidence of venous thromboembolism (VTE) is very common in cancer patients, as they are at higher risk of developing VTE compared to the general population. Multiple overlapping thrombotic & hemostatic pathophysiological pathways and several risk factors that are specific to this patient population increase the risk of VTE.
Therefore, it requires a daily injection of low-molecular-weight heparin (LMWH) for 6 months instead of an oral anticoagulant. Thus, the rising burden of cancer incidence and mortality rate at a rapid pace across the globe is anticipated to boost the intravenous anticoagulant market during the forecast period.
For instance, according to data published by the Pan American Health Organization in 2023, the cancer burden is projected to increase by around 60% over the next two decades. Moreover, the global number of cancer cases is anticipated to reach 30 million by 2040, with the high increase occurring in low- and middle-income countries.
Market Restraint- Stringent Regulatory Framework
Strict regulations on intravenous anticoagulants, including drug price regulation, quality control, and FDA rules and regulations, affect the market.
For instance, in India, the Drug Price Control Order (DPCO) are issued under the Essential Commodities Act, 1955. In addition to that all dosages which are mentioned in the National List of Essential Medicines (NLEM) will be under price control.
The National Pharmaceutical Pricing Authority (NPPA) is the price regulator of India. Price controls over pharmaceuticals are often arbitrary and unpredictable, which makes it challenging for the pharmaceutical industry to do business in India.
The Union Ministry of Health issued a notification to ensure the quality of drugs, which requires conducting bio-equivalence (BE) studies for generic drugs that are approved by the State FDA.
Market Opportunity- Development of NOACs Reversal Agents
The development of NOAC reversal agents to increase the safety of patients creates a lucrative opportunity in the intravenous anticoagulant market. The non-vitamin K antagonist oral anticoagulants (NOACs), such as dabigatran inhibit thrombin, and betrixaban, apixaban, rivaroxaban, and edoxaban inhibit coagulation factor Xa.
However, NOACs clinical studies were conducted without antidotes and major bleeding issues are mostly found in patients who receive NOACs and are no worse than those patients who treated with a vitamin K antagonist.
Scope of the Intravenous Anticoagulants Market Report
The report on the global Intravenous Anticoagulants market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes |
Details |
|
Report Title |
Intravenous Anticoagulants Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast |
|
Base Year |
2022 |
|
Historic Data |
2016-2021 |
|
Forecast Period |
2023–2031 |
|
Segmentation |
By Type (Heparin, Fondaparinux, Direct Thrombin Inhibitors), By Application (Unfractionated Heparin (UFH), Low Molecular Weight Heparin (LMWH), Fondaparinux, and Direct Thrombin Inhibitors), By End use (Hospital, Clinics, and Ambulatory Centers), |
|
Regional Scope |
Regions (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
|
Key Players Covered |
Abbott, AstraZeneca, B. Braun SE, Baxter International Inc., Bayer AG, Bristol-Myers Squibb Company, Fresenius SE & Co. KGaA., GSK plc, Johnson & Johnson, Novartis AG, Pfizer Inc., and Viatris Inc. |
Intravenous Anticoagulants Market Segmental Outlook
Based on Type, the market is segmented into heparin, fondaparinux, and direct thrombin inhibitors. The heparin segment is expected to hold a considerable share of the market during the forecast, as heparin is often preferred as an intravenous anticoagulant in specific clinical situations when compared to fondaparinux and direct thrombin inhibitors such as argatroban or bivalirudin.
On the basis of Application, the market is fragmented into unfractionated heparin (UFH), low molecular weight heparin (LMWH), fondaparinux, and direct thrombin inhibitors. The open-heart CABG subsegment held the significant share of the market in 2022. UFH has a rapid onset of action, making it suitable for immediate anticoagulation during open-heart surgery.
For instance, according to the University of Alabama at Birmingham, nearly 350,000 CABG surgeries are performed annually in the US, which is boosting the demand for Unfractionated Heparin (UFH). All these factors are expected to drive the open-heart CABG sub-segment during the forecast period.
In terms of End-use, the market is classified as hospitals, clinics, and ambulatory centers. The hospitals segment is anticipated to expand at a significant CAGR during the forecast period, owing to the rising cardiovascular diseases, which leads to a rise in cardiac surgery procedures.
For instance, according to research by Teleflex Incorporated, a US-based medical device company, more than 600,000 open cardiothoracic procedures are performed in the US each year.
Regional Outlook
Based on regions, the market is fragmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounted for a significant share of the market in 2022. The intravenous anticoagulants market in North America is influenced by several factors that contribute to its growth.
The growth of the market in the US is attributed to the growing number of cardiovascular diseases in the country. Treatment for cardiovascular diseases often includes immediate anticoagulation therapy to prevent further clotting and complications.
As per the American Heart Association, cardiovascular disease (CVD) remains the leading cause of death in the US, accounting for 928,741 deaths in 2020.
Key Developments:
-
In 2023, Fresenius Kabi entered into a license agreement with Formycon AG to commercialize a proposed Ustekinumab biosimilar candidate.
-
In 2023, Pfizer Inc. acquired a biologics drug substance manufacturing facility in Sanford, North Carolina from Abzena.
-
In 2022, Viatris Inc. sold its international biosimilars business to Biocon Biologics.
-
In 2022, Fresenius Kabi entered into a partnership with Bio-Manguinhos and Bionovis for the production and supply of the company’s adalimumab biosimilar, IDACIO in Brazil.
-
In 2019, Fresenius Kabi Introduces Heparin Sodium Injection, USP Simplist Prefilled Syringe in 5,000 USP units per 0.5 mL dose.
-
In 2021, GSK Plc. secured approval from European Medicines Agency for its intravenous and subcutaneous Benlysta (belimumab) in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephriti.
Key Benefits for Industry Participants & Stakeholders
-
In-depth Analysis of the Global Intravenous Anticoagulants Market
-
Historical, Current, and Projected Market Size in Terms of Value
-
Potential & Niche Segments and Regions Exhibiting Promising Growth Covered
-
Industry Drivers, Restraints, and Opportunities Covered in the Study
-
Recent Industry Trends and Developments
-
Competitive Landscape & Strategies of Key Players
Segments
By Type
- Heparin
- Fondaparinux
- Direct Thrombin Inhibitors
By Application
- Unfractionated Heparin (UFH)
- Low Molecular Weight Heparin (LMWH)
- Fondaparinux
- Direct Thrombin Inhibitors
By End-use
- Hospital
- Clinics
- Ambulatory Centers
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Key Market Players Profiled in the Report
Competitive Landscape
-
Manufacturers operating in the global Intravenous Anticoagulants market are Abbott, AstraZeneca, B. Braun SE, Baxter International Inc., Bayer AG, Bristol-Myers Squibb Company, Fresenius SE & Co. KGaA., GSK plc, Johnson & Johnson, Novartis AG, Pfizer Inc., and Viatris Inc.
-
Market players are pursuing strategies such as acquisitions, product launches, collaborations, and geographic expansion to leverage untapped opportunities in the global Intravenous Anticoagulants market.
Frequently Asked Questions
Additional company profiles can be provided on request. For a discussion related to the above findings, click Speak to Analyst
Factors such as competitive strength and market positioning are key areas considered while selecting top companies to be profiled.
Increasing Incidence Of Cardiovascular Diseases is the factors expected to drive the market growth during the forecast period.
According to this Growth Market Reports report, the global Intravenous Anticoagulants market is likely to register a CAGR of 5.96% during the forecast period 2023-2031, with a projected valuation of USD ~22,682.0 million by the end of 2031.
Factors such as Population Demographics is analyzed in the final report.
Major manufacturers include Abbott, AstraZeneca, B. Braun SE, Baxter International Inc., Bayer AG, Bristol-Myers Squibb Company, Fresenius SE & Co. KGaA., GSK plc, Johnson & Johnson, Novartis AG, Pfizer Inc., and Viatris Inc.
The pandemic had a significant impact on various markets, including the Intravenous Anticoagulants market. The COVID-19 Treatment Guidelines Panel (the Panel) advised patients with COVID-19 who are receiving anticoagulant or antiplatelet therapy for underlying illnesses to continue taking these drugs until severe bleeding occurs or other contraindications exist.
In addition to market size (in US$ Million), impact of key regulations, pricing analysis, is provided in the final report.
The forecast year considered for the global Intravenous Anticoagulants market report is 2031.
The base year considered for the global Intravenous Anticoagulants market report is 2022. The complete analysis period is 2016 to 2031, wherein, 2016 to 2021 are the historic years, and the forecast is provided from 2023 to 2031.
Table Of Content
Chapter 1 Executive SummaryChapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Intravenous Anticoagulants Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Intravenous Anticoagulants Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Intravenous Anticoagulants Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Intravenous Anticoagulants Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Intravenous Anticoagulants Market Size & Forecast, 2016-2031
4.5.1 Intravenous Anticoagulants Market Size and Y-o-Y Growth
4.5.2 Intravenous Anticoagulants Market Absolute $ Opportunity
4.6 Global Intravenous Anticoagulants Market: Impact Of Key Regulations
4.7 Pricing Analysis
4.8 Epidemiology of Venous Thromboembolism
4.9 Oral Anticoagulants: Overview
4.10 Opportunities for Key Players Operating in Oral Anticoagulants Industry to Enter in Intravenous Anticoagulants Market
Chapter 5 Global Intravenous Anticoagulants Market Analysis and Forecast By Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities By Type
5.1.2 Basis Point Share (BPS) Analysis By Type
5.1.3 Absolute $ Opportunity Assessment By Type
5.2 Intravenous Anticoagulants Market Size & Volume Forecast By Type
5.2.1 Heparin
5.2.1.1 Unfractionated Heparin (UFH)
5.2.1.2 Low Molecular Weight Heparin (LMWH)
5.2.2 Fondaparinux
5.2.3 Direct Thrombin Inhibitors
5.2.3.1 Argatroban
5.2.3.2 Desirudin
5.2.3.3 Bivalirudin
5.3 Market Attractiveness Analysis By Type
Chapter 6 Global Intravenous Anticoagulants Market Analysis and Forecast By Application
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities By Application
6.1.2 Basis Point Share (BPS) Analysis By Application
6.1.3 Absolute $ Opportunity Assessment By Application
6.2 Intravenous Anticoagulants Market Size & Volume Forecast By Application
6.2.1 Unfractionated Heparin (UFH)
6.2.1.1 Open Heart CABG
6.2.1.2 Open Heart Value Replacement/Repair
6.2.1.3 Transcatheter Value Replacement
6.2.1.4 Carotid Artery
6.2.1.5 Transmyocardial Revascularization
6.2.1.6 Aneurysm Surgery
6.2.1.7 Left Atrial Appendage
6.2.1.8 Atrial Fibrillation Ablation
6.2.1.9 Pace Maker
6.2.1.10 Percutaneous Coronary Intervention (PCI)
6.2.1.11 Extracorporeal Membrane Oxygenation (ECMO)
6.2.1.12 Venous Thromboembolism (VTE)
6.2.1.13 Hypercoagulable Conditions
6.2.2 Low Molecular Weight Heparin (LMWH)
6.2.2.1 Open Heart CABG
6.2.2.2 Open Heart Value Replacement/Repair
6.2.2.3 Transcatheter Value Replacement
6.2.2.4 Carotid Artery
6.2.2.5 Transmyocardial Revascularization
6.2.2.6 Aneurysm Surgery
6.2.2.7 Left Atrial Appendage
6.2.2.8 Atrial Fibrillation Ablation
6.2.2.9 Pace Maker
6.2.2.10 Percutaneous Coronary Intervention (PCI)
6.2.2.11 Extracorporeal Membrane Oxygenation (ECMO)
6.2.2.12 Venous Thromboembolism (VTE)
6.2.2.13 Hypercoagulable Conditions
6.2.3 Fondaparinux
6.2.3.1 Venous Thromboembolism
6.2.3.2 Deep Vein Thrombosis/Acute Pulmonary Embolism
6.2.3.3 Myocardial Infarction
6.2.4 Direct Thrombin Inhibitors
6.2.4.1 Acute Coronary Syndrome
6.2.4.2 Heparin-induced thrombocytopenia (HIT)
6.2.4.3 Venous thromboembolism (VTE)
6.2.4.4 Atrial Fibrillation (Afib)
6.2.4.5 Hip Replacement Surgery
6.2.4.6 Angioplasty
6.3 Market Attractiveness Analysis By Application
Chapter 7 Global Intravenous Anticoagulants Market Analysis and Forecast By End use
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities By End use
7.1.2 Basis Point Share (BPS) Analysis By End use
7.1.3 Absolute $ Opportunity Assessment By End use
7.2 Intravenous Anticoagulants Market Size & Volume Forecast By End use
7.2.1 Hospital
7.2.2 Clinics
7.2.3 Ambulatory Centers
7.3 Market Attractiveness Analysis By End use
Chapter 8 Global Intravenous Anticoagulants Market Analysis and Forecast by Region
8.1 Introduction
8.1.1 Key Market Trends & Growth Opportunities by Region
8.1.2 Basis Point Share (BPS) Analysis by Region
8.1.3 Absolute $ Opportunity Assessment by Region
8.2 Intravenous Anticoagulants Market Size & Volume Forecast by Region
8.2.1 North America
8.2.2 Europe
8.2.3 Asia Pacific
8.2.4 Latin America
8.2.5 Middle East & Africa (MEA)
8.3 Market Attractiveness Analysis by Region
Chapter 9 Coronavirus Disease (COVID-19) Impact
9.1 Introduction
9.2 Current & Future Impact Analysis
9.3 Economic Impact Analysis
9.4 Government Policies
9.5 Investment Scenario
Chapter 10 North America Intravenous Anticoagulants Analysis and Forecast
10.1 Introduction
10.2 North America Intravenous Anticoagulants Market Size & Volume Forecast by Country
10.2.1 U.S.
10.2.2 Canada
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 North America Intravenous Anticoagulants Market Size & Volume Forecast By Type
10.6.1 Heparin
10.6.1.1 Unfractionated Heparin (UFH)
10.6.1.2 Low Molecular Weight Heparin (LMWH)
10.6.2 Fondaparinux
10.6.3 Direct Thrombin Inhibitors
10.6.3.1 Argatroban
10.6.3.2 Desirudin
10.6.3.3 Bivalirudin
10.7 Basis Point Share (BPS) Analysis By Type
10.8 Absolute $ Opportunity Assessment By Type
10.9 Market Attractiveness Analysis By Type
10.10 North America Intravenous Anticoagulants Market Size & Volume Forecast By Application
10.10.1 Unfractionated Heparin (UFH)
10.10.1.1 Open Heart CABG
10.10.1.2 Open Heart Value Replacement/Repair
10.10.1.3 Transcatheter Value Replacement
10.10.1.4 Carotid Artery
10.10.1.5 Transmyocardial Revascularization
10.10.1.6 Aneurysm Surgery
10.10.1.7 Left Atrial Appendage
10.10.1.8 Atrial Fibrillation Ablation
10.10.1.9 Pace Maker
10.10.1.10 Percutaneous Coronary Intervention (PCI)
10.10.1.11 Extracorporeal Membrane Oxygenation (ECMO)
10.10.1.12 Venous Thromboembolism (VTE)
10.10.1.13 Hypercoagulable Conditions
10.10.2 Low Molecular Weight Heparin (LMWH)
10.10.2.1 Open Heart CABG
10.10.2.2 Open Heart Value Replacement/Repair
10.10.2.3 Transcatheter Value Replacement
10.10.2.4 Carotid Artery
10.10.2.5 Transmyocardial Revascularization
10.10.2.6 Aneurysm Surgery
10.10.2.7 Left Atrial Appendage
10.10.2.8 Atrial Fibrillation Ablation
10.10.2.9 Pace Maker
10.10.2.10 Percutaneous Coronary Intervention (PCI)
10.10.2.11 Extracorporeal Membrane Oxygenation (ECMO)
10.10.2.12 Venous Thromboembolism (VTE)
10.10.2.13 Hypercoagulable Conditions
10.10.3 Fondaparinux
10.10.3.1 Venous Thromboembolism
10.10.3.2 Deep Vein Thrombosis/Acute Pulmonary Embolism
10.10.3.3 Myocardial Infarction
10.10.4 Direct Thrombin Inhibitors
10.10.4.1 Acute Coronary Syndrome
10.10.4.2 Heparin-induced thrombocytopenia (HIT)
10.10.4.3 Venous thromboembolism (VTE)
10.10.4.4 Atrial Fibrillation (Afib)
10.10.4.5 Hip Replacement Surgery
10.10.4.6 Angioplasty
10.11 Basis Point Share (BPS) Analysis By Application
10.12 Absolute $ Opportunity Assessment By Application
10.13 Market Attractiveness Analysis By Application
10.14 North America Intravenous Anticoagulants Market Size & Volume Forecast By End use
10.14.1 Hospital
10.14.2 Clinics
10.14.3 Ambulatory Centers
10.15 Basis Point Share (BPS) Analysis By End use
10.16 Absolute $ Opportunity Assessment By End use
10.17 Market Attractiveness Analysis By End use
Chapter 11 Europe Intravenous Anticoagulants Analysis and Forecast
11.1 Introduction
11.2 Europe Intravenous Anticoagulants Market Size & Volume Forecast by Country
11.2.1 Germany
11.2.2 France
11.2.3 Italy
11.2.4 U.K.
11.2.5 Spain
11.2.6 Russia
11.2.7 Rest of Europe
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Europe Intravenous Anticoagulants Market Size & Volume Forecast By Type
11.6.1 Heparin
11.6.1.1 Unfractionated Heparin (UFH)
11.6.1.2 Low Molecular Weight Heparin (LMWH)
11.6.2 Fondaparinux
11.6.3 Direct Thrombin Inhibitors
11.6.3.1 Argatroban
11.6.3.2 Desirudin
11.6.3.3 Bivalirudin
11.7 Basis Point Share (BPS) Analysis By Type
11.8 Absolute $ Opportunity Assessment By Type
11.9 Market Attractiveness Analysis By Type
11.10 Europe Intravenous Anticoagulants Market Size & Volume Forecast By Application
11.10.1 Unfractionated Heparin (UFH)
11.10.1.1 Open Heart CABG
11.10.1.2 Open Heart Value Replacement/Repair
11.10.1.3 Transcatheter Value Replacement
11.10.1.4 Carotid Artery
11.10.1.5 Transmyocardial Revascularization
11.10.1.6 Aneurysm Surgery
11.10.1.7 Left Atrial Appendage
11.10.1.8 Atrial Fibrillation Ablation
11.10.1.9 Pace Maker
11.10.1.10 Percutaneous Coronary Intervention (PCI)
11.10.1.11 Extracorporeal Membrane Oxygenation (ECMO)
11.10.1.12 Venous Thromboembolism (VTE)
11.10.1.13 Hypercoagulable Conditions
11.10.2 Low Molecular Weight Heparin (LMWH)
11.10.2.1 Open Heart CABG
11.10.2.2 Open Heart Value Replacement/Repair
11.10.2.3 Transcatheter Value Replacement
11.10.2.4 Carotid Artery
11.10.2.5 Transmyocardial Revascularization
11.10.2.6 Aneurysm Surgery
11.10.2.7 Left Atrial Appendage
11.10.2.8 Atrial Fibrillation Ablation
11.10.2.9 Pace Maker
11.10.2.10 Percutaneous Coronary Intervention (PCI)
11.10.2.11 Extracorporeal Membrane Oxygenation (ECMO)
11.10.2.12 Venous Thromboembolism (VTE)
11.10.2.13 Hypercoagulable Conditions
11.10.3 Fondaparinux
11.10.3.1 Venous Thromboembolism
11.10.3.2 Deep Vein Thrombosis/Acute Pulmonary Embolism
11.10.3.3 Myocardial Infarction
11.10.4 Direct Thrombin Inhibitors
11.10.4.1 Acute Coronary Syndrome
11.10.4.2 Heparin-induced thrombocytopenia (HIT)
11.10.4.3 Venous thromboembolism (VTE)
11.10.4.4 Atrial Fibrillation (Afib)
11.10.4.5 Hip Replacement Surgery
11.10.4.6 Angioplasty
11.11 Basis Point Share (BPS) Analysis By Application
11.12 Absolute $ Opportunity Assessment By Application
11.13 Market Attractiveness Analysis By Application
11.14 Europe Intravenous Anticoagulants Market Size & Volume Forecast By End use
11.14.1 Hospital
11.14.2 Clinics
11.14.3 Ambulatory Centers
11.15 Basis Point Share (BPS) Analysis By End use
11.16 Absolute $ Opportunity Assessment By End use
11.17 Market Attractiveness Analysis By End use
Chapter 12 Asia Pacific Intravenous Anticoagulants Analysis and Forecast
12.1 Introduction
12.2 Asia Pacific Intravenous Anticoagulants Market Size & Volume Forecast by Country
12.2.1 China
12.2.2 Japan
12.2.3 South Korea
12.2.4 India
12.2.5 Australia
12.2.6 South East Asia (SEA)
12.2.7 Rest of Asia Pacific (APAC)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Asia Pacific Intravenous Anticoagulants Market Size & Volume Forecast By Type
12.6.1 Heparin
12.6.1.1 Unfractionated Heparin (UFH)
12.6.1.2 Low Molecular Weight Heparin (LMWH)
12.6.2 Fondaparinux
12.6.3 Direct Thrombin Inhibitors
12.6.3.1 Argatroban
12.6.3.2 Desirudin
12.6.3.3 Bivalirudin
12.7 Basis Point Share (BPS) Analysis By Type
12.8 Absolute $ Opportunity Assessment By Type
12.9 Market Attractiveness Analysis By Type
12.10 Asia Pacific Intravenous Anticoagulants Market Size & Volume Forecast By Application
12.10.1 Unfractionated Heparin (UFH)
12.10.1.1 Open Heart CABG
12.10.1.2 Open Heart Value Replacement/Repair
12.10.1.3 Transcatheter Value Replacement
12.10.1.4 Carotid Artery
12.10.1.5 Transmyocardial Revascularization
12.10.1.6 Aneurysm Surgery
12.10.1.7 Left Atrial Appendage
12.10.1.8 Atrial Fibrillation Ablation
12.10.1.9 Pace Maker
12.10.1.10 Percutaneous Coronary Intervention (PCI)
12.10.1.11 Extracorporeal Membrane Oxygenation (ECMO)
12.10.1.12 Venous Thromboembolism (VTE)
12.10.1.13 Hypercoagulable Conditions
12.10.2 Low Molecular Weight Heparin (LMWH)
12.10.2.1 Open Heart CABG
12.10.2.2 Open Heart Value Replacement/Repair
12.10.2.3 Transcatheter Value Replacement
12.10.2.4 Carotid Artery
12.10.2.5 Transmyocardial Revascularization
12.10.2.6 Aneurysm Surgery
12.10.2.7 Left Atrial Appendage
12.10.2.8 Atrial Fibrillation Ablation
12.10.2.9 Pace Maker
12.10.2.10 Percutaneous Coronary Intervention (PCI)
12.10.2.11 Extracorporeal Membrane Oxygenation (ECMO)
12.10.2.12 Venous Thromboembolism (VTE)
12.10.2.13 Hypercoagulable Conditions
12.10.3 Fondaparinux
12.10.3.1 Venous Thromboembolism
12.10.3.2 Deep Vein Thrombosis/Acute Pulmonary Embolism
12.10.3.3 Myocardial Infarction
12.10.4 Direct Thrombin Inhibitors
12.10.4.1 Acute Coronary Syndrome
12.10.4.2 Heparin-induced thrombocytopenia (HIT)
12.10.4.3 Venous thromboembolism (VTE)
12.10.4.4 Atrial Fibrillation (Afib)
12.10.4.5 Hip Replacement Surgery
12.10.4.6 Angioplasty
12.11 Basis Point Share (BPS) Analysis By Application
12.12 Absolute $ Opportunity Assessment By Application
12.13 Market Attractiveness Analysis By Application
12.14 Asia Pacific Intravenous Anticoagulants Market Size & Volume Forecast By End use
12.14.1 Hospital
12.14.2 Clinics
12.14.3 Ambulatory Centers
12.15 Basis Point Share (BPS) Analysis By End use
12.16 Absolute $ Opportunity Assessment By End use
12.17 Market Attractiveness Analysis By End use
Chapter 13 Latin America Intravenous Anticoagulants Analysis and Forecast
13.1 Introduction
13.2 Latin America Intravenous Anticoagulants Market Size & Volume Forecast by Country
13.2.1 Brazil
13.2.2 Mexico
13.2.3 Rest of Latin America (LATAM)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Latin America Intravenous Anticoagulants Market Size & Volume Forecast By Type
13.6.1 Heparin
13.6.1.1 Unfractionated Heparin (UFH)
13.6.1.2 Low Molecular Weight Heparin (LMWH)
13.6.2 Fondaparinux
13.6.3 Direct Thrombin Inhibitors
13.6.3.1 Argatroban
13.6.3.2 Desirudin
13.6.3.3 Bivalirudin
13.7 Basis Point Share (BPS) Analysis By Type
13.8 Absolute $ Opportunity Assessment By Type
13.9 Market Attractiveness Analysis By Type
13.10 Latin America Intravenous Anticoagulants Market Size & Volume Forecast By Application
13.10.1 Unfractionated Heparin (UFH)
13.10.1.1 Open Heart CABG
13.10.1.2 Open Heart Value Replacement/Repair
13.10.1.3 Transcatheter Value Replacement
13.10.1.4 Carotid Artery
13.10.1.5 Transmyocardial Revascularization
13.10.1.6 Aneurysm Surgery
13.10.1.7 Left Atrial Appendage
13.10.1.8 Atrial Fibrillation Ablation
13.10.1.9 Pace Maker
13.10.1.10 Percutaneous Coronary Intervention (PCI)
13.10.1.11 Extracorporeal Membrane Oxygenation (ECMO)
13.10.1.12 Venous Thromboembolism (VTE)
13.10.1.13 Hypercoagulable Conditions
13.10.2 Low Molecular Weight Heparin (LMWH)
13.10.2.1 Open Heart CABG
13.10.2.2 Open Heart Value Replacement/Repair
13.10.2.3 Transcatheter Value Replacement
13.10.2.4 Carotid Artery
13.10.2.5 Transmyocardial Revascularization
13.10.2.6 Aneurysm Surgery
13.10.2.7 Left Atrial Appendage
13.10.2.8 Atrial Fibrillation Ablation
13.10.2.9 Pace Maker
13.10.2.10 Percutaneous Coronary Intervention (PCI)
13.10.2.11 Extracorporeal Membrane Oxygenation (ECMO)
13.10.2.12 Venous Thromboembolism (VTE)
13.10.2.13 Hypercoagulable Conditions
13.10.3 Fondaparinux
13.10.3.1 Venous Thromboembolism
13.10.3.2 Deep Vein Thrombosis/Acute Pulmonary Embolism
13.10.3.3 Myocardial Infarction
13.10.4 Direct Thrombin Inhibitors
13.10.4.1 Acute Coronary Syndrome
13.10.4.2 Heparin-induced thrombocytopenia (HIT)
13.10.4.3 Venous thromboembolism (VTE)
13.10.4.4 Atrial Fibrillation (Afib)
13.10.4.5 Hip Replacement Surgery
13.10.4.6 Angioplasty
13.11 Basis Point Share (BPS) Analysis By Application
13.12 Absolute $ Opportunity Assessment By Application
13.13 Market Attractiveness Analysis By Application
13.14 Latin America Intravenous Anticoagulants Market Size & Volume Forecast By End use
13.14.1 Hospital
13.14.2 Clinics
13.14.3 Ambulatory Centers
13.15 Basis Point Share (BPS) Analysis By End use
13.16 Absolute $ Opportunity Assessment By End use
13.17 Market Attractiveness Analysis By End use
Chapter 14 Middle East & Africa (MEA) Intravenous Anticoagulants Analysis and Forecast
14.1 Introduction
14.2 Middle East & Africa (MEA) Intravenous Anticoagulants Market Size & Volume Forecast by Country
14.2.1 Saudi Arabia
14.2.2 South Africa
14.2.3 UAE
14.2.4 Rest of Middle East & Africa (MEA)
14.3 Basis Point Share (BPS) Analysis by Country
14.4 Absolute $ Opportunity Assessment by Country
14.5 Market Attractiveness Analysis by Country
14.6 Middle East & Africa (MEA) Intravenous Anticoagulants Market Size & Volume Forecast By Type
14.6.1 Heparin
14.6.1.1 Unfractionated Heparin (UFH)
14.6.1.2 Low Molecular Weight Heparin (LMWH)
14.6.2 Fondaparinux
14.6.3 Direct Thrombin Inhibitors
14.6.3.1 Argatroban
14.6.3.2 Desirudin
14.6.3.3 Bivalirudin
14.7 Basis Point Share (BPS) Analysis By Type
14.8 Absolute $ Opportunity Assessment By Type
14.9 Market Attractiveness Analysis By Type
14.10 Middle East & Africa (MEA) Intravenous Anticoagulants Market Size & Volume Forecast By Application
14.10.1 Unfractionated Heparin (UFH)
14.10.1.1 Open Heart CABG
14.10.1.2 Open Heart Value Replacement/Repair
14.10.1.3 Transcatheter Value Replacement
14.10.1.4 Carotid Artery
14.10.1.5 Transmyocardial Revascularization
14.10.1.6 Aneurysm Surgery
14.10.1.7 Left Atrial Appendage
14.10.1.8 Atrial Fibrillation Ablation
14.10.1.9 Pace Maker
14.10.1.10 Percutaneous Coronary Intervention (PCI)
14.10.1.11 Extracorporeal Membrane Oxygenation (ECMO)
14.10.1.12 Venous Thromboembolism (VTE)
14.10.1.13 Hypercoagulable Conditions
14.10.2 Low Molecular Weight Heparin (LMWH)
14.10.2.1 Open Heart CABG
14.10.2.2 Open Heart Value Replacement/Repair
14.10.2.3 Transcatheter Value Replacement
14.10.2.4 Carotid Artery
14.10.2.5 Transmyocardial Revascularization
14.10.2.6 Aneurysm Surgery
14.10.2.7 Left Atrial Appendage
14.10.2.8 Atrial Fibrillation Ablation
14.10.2.9 Pace Maker
14.10.2.10 Percutaneous Coronary Intervention (PCI)
14.10.2.11 Extracorporeal Membrane Oxygenation (ECMO)
14.10.2.12 Venous Thromboembolism (VTE)
14.10.2.13 Hypercoagulable Conditions
14.10.3 Fondaparinux
14.10.3.1 Venous Thromboembolism
14.10.3.2 Deep Vein Thrombosis/Acute Pulmonary Embolism
14.10.3.3 Myocardial Infarction
14.10.4 Direct Thrombin Inhibitors
14.10.4.1 Acute Coronary Syndrome
14.10.4.2 Heparin-induced thrombocytopenia (HIT)
14.10.4.3 Venous thromboembolism (VTE)
14.10.4.4 Atrial Fibrillation (Afib)
14.10.4.5 Hip Replacement Surgery
14.10.4.6 Angioplasty
14.11 Basis Point Share (BPS) Analysis By Application
14.12 Absolute $ Opportunity Assessment By Application
14.13 Market Attractiveness Analysis By Application
14.14 Middle East & Africa (MEA) Intravenous Anticoagulants Market Size & Volume Forecast By End use
14.14.1 Hospital
14.14.2 Clinics
14.14.3 Ambulatory Centers
14.15 Basis Point Share (BPS) Analysis By End use
14.16 Absolute $ Opportunity Assessment By End use
14.17 Market Attractiveness Analysis By End use
Chapter 15 Competition Landscape
15.1 Intravenous Anticoagulants Market: Competitive Dashboard
15.2 Global Intravenous Anticoagulants Market: Market Share Analysis, 2022
15.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
15.3.1 Abbott
15.3.2 Astra Zeneca
15.3.3 B. Braun SE
15.3.4 Baxter
15.3.5 Bayer
15.3.6 Bristol Myers Squib
15.3.7 Fresenius Kabi
15.3.8 GSK plc.
15.3.9 J&J (Janssen)
15.3.10 Novartis
15.3.11 Pfizer Inc.
15.3.12 Viatris Inc.
Methodology
Related Reports
Some other reports from this category!
Our Clients
